Pharma Conference Coverage Strategy

We live in a world of data that threatens to overwhelm our work and personal lives.  Part of the reason for this is the price of data storage continues to fall dramatically.

Today, an external hard drive offers a 1TB capacity; a few years ago the same product offered 100GB.  A 10x increase in storage capacity for the same money in the space of a few years.

Data is now available from online posters, abstracts, webcasts and presentations. We also have Facebook, Twitter, Linkedin and other social media competing for our time.

ASCO 2011 Conference Chicago 300x225 Pharma Conference Coverage StrategyASCO 2011: “the never ending walk”

What this means is that if you plan to attend a major medical or scientific meeting such as the annual meeting of the American Society of Clinical Oncology (ASCO), which offers a lot of data, you need to have a conference coverage strategy.

Here are a few tips we suggest you consider:

Don’t go for a “Data Dump”

Too often we see a “fear of missing out” (FOMO) mentality drive a “we must capture everything” policy.  All this results in is a mass of data that somebody has to analyze after the meeting.  Too often a 300+ page data dump report (when it finally is produced) ends up sitting on the metaphorical shelf.

Focus on Key Questions

Prior to a major medical or scientific meeting it’s important to develop a list of the key questions that a brand, commercial or new products team need answered.  The questions could be on competitor activity, developments in a pathway or impact of clinical data on the standard of care.  Data collection can then be focusoned on answering those key questions.

Insights cost more

Recently, staff at a top 20 pharma company told us they were paying $X for a conference “data dump” but only had 10% of $X available for strategic insights.  In Twitter speak, they had #LostThePlot as it should be the other way round since insights are more valuable than raw data.

As management consultants, we might produce a Powerpoint slide with a table or chart based on data from 20 posters. In order to select those 20 key posters, we could have reviewed perhaps 200 posters originally.  Which would you rather have, one slide with insights and analysis or 200 Powerpoint slides with data? Our philosophy is “less is more.” 

Insights cost more because it takes in-depth therapeutic area knowledge and expertise to condense data into a meaningful story and make strategic recommendations.

What is your conference coverage strategy for this year? Please contact us if you would like to learn more about our capabilities.

Everolimus plus exemestane is the biggest advance in breast cancer since Herceptin

2011 European Multidisciplinary Cancer Congress Breast cancer news 

Goodbye from Stockholm Cancer Congress 2011 300x225 Everolimus plus exemestane is the biggest advance in breast cancer since HerceptinThere were two noteworthy breast trials with new data at the 2011 ESMO ECCO oncology congress in Stockholm this past weekend:

1) The phase III BOLERO-2 study for everolimus (Afinitor) plus exemestane is according to Sally Church, “probably the biggest single advance in breast since the Herceptin data was announced way back in the 1990’s,” with an improvement in progression free survival (PFS) from 4.1 to 10.6 months, a six and a half month extra benefit.

2) The other trial that returned good solid data was a phase II study that compared T-DM1 to trastuzumab plus docetaxel in women with HER2+ breast cancer who were previously untreated.  The median PFS improved from 9.2 to 14.2 months, an improvement of 5 months before the disease worsened.  The side effect profile, including cardiotoxicity, was also superior in the T-DM1 arm compared to the control arm.  We still need to wait for the phase III results before drawing definitive conclusions on the safety and efficacy of T-DM1, but the results so far are promising.

Although there are multiple therapies are available for the treatment of different types of metastatic breast cancer, many of them sadly only advance progression by a few months at a time, meaning patients must cycle through multiple lines of therapy.

The good news is that these agents are being tested in different patient populations, meaning we will have new and potentially better options for more patients. It is hoped both everolimus and trastuzumab will be approved for breast cancer in the not to distant future.

You can read more about the impressive breast cancer results in the BOLERO-2 study on Pharma Strategy Blog. This data was Sally Church’s HOT NEWS of the Stockholm cancer congress!

Icarus Consultants will be at the San Antonio Breast Cancer Symposium (SABCS) later this year, where we expect more insights and new data in breast cancer new product development.

Conference Coverage: the week in review

Now that summer is officially over, the fall pharma/biotech conference season has started. You can find out details of the conferences Icarus Consultants will be attending by checking out our conference schedule.

If you are interested in our meeting coverage services or a conference report, please contact us.

Boston Prudential Center 169x300 Conference Coverage: the week in reviewThis week, we followed two conferences remotely through Twitter.  On Biotech Strategy Blog, Pieter Droppert aggregated the tweets from the BioPharm America 2011 partnering conference in Boston.

The joy of twitter is that you can follow the key messages of conference presenters remotely. It’s no substitute for being at the meeting and the networking opportunities in person, but it does allow you to capture a flavor of what everyone is thinking.  140 characters allows for a good sound bite!

Meanwhile on Pharma Strategy Blog, Sally Church has been following the ASCO Breast Cancer Symposium 2011 in San Francisco.  Icarus Consultants will be at the San Antonio Breast Cancer Symposium (SABCS) later this year.

On Pharma Strategy Blog, Sally also wrote about the European Multidisciplinary Cancer Conference in Stockholm, more commonly known as ECCO or ESMO.  The conference abstracts will be available on Monday, so we look forward to Sally’s video preview and thoughts on what’s hot at the meeting.

Memories of 9/11

Sally Church Kite Flying Liberty Park WTC in Background 225x300 Memories of 9/11Those of us who lived around New York City ten years ago will never forget the sight of the World Trade Center towers coming down. It is forever indelibly etched in our minds.

Many of us had dined at “Windows on the World” or been to the Observation Deck and watched light aircraft flying along the Hudson, below us. Many knew people who did not make it out.

It is a trauma that we will never forget, and Sept 11 is a day of remembrance. However, life is a journey and we must look forwards not back.

Icarus Consultants closed on Labor Day

Bidston Hill Windmill © Pieter Droppert 225x300 Icarus Consultants closed on Labor DayAfter all the “excitement” of hurricane Irene last week in the New Jersey/New York metro area, this weekend offers the Labor Day holiday. It is to many the last hurrah of summer.

According to the United States Department of Labor, the public holiday on the first Monday in September pays tribute to the American worker, “creator of so much of the nation’s strength, freedom, and leadership.”

Economic prosperity and access to healthcare are very much linked with employment in the United States, so it is sad to see the recent poor job creation results.

Icarus Consultants will be closed on Monday, September 5 and will reopen for business on Tuesday. We wish all our current and prospective pharma and biotech consulting clients an enjoyable weekend.

Sally Church invited to be distinguished speaker at MD Anderson Cancer Center Science Park

Science Park UT MD Anderson Cancer Center Sally Church invited to be distinguished speaker at MD Anderson Cancer Center Science ParkIt is a pleasure to announce that Sally Church, PhD has been invited to be a speaker in the Distinguished Lecturer Student Seminar Series held at the Science Park campus of the University of Texas, MD Anderson Cancer Center.

The Science Park located at Smithville, just outside of Austin, TX is the location of the Victoria Harris Cockrell Cancer Research Center, where basic science research is undertaken in the Department of Molecular Carcinogenesis.

The mission of the center is “to investigate the molecular biology of cancer and to develop means for cancer prevention and detection.

Sally’s seminar on October 5, 2011 to the graduate students in cancer research is entitled, “On Science, Blogging and Drug Development.

We look forward to reading more about Sally’s visit and seminar on Pharma Strategy Blog.

The arrival of Irene in NYC means Icarus Consultants will be closed on Monday August 29

Last Ship Leaves NYC before Irene The arrival of Irene in NYC means Icarus Consultants will be closed on Monday August 29With the uncertainty surrounding the impact that hurricane or tropical storm Irene may have on the New Jersey/New York City metro area, Icarus Consultants will be closed on Monday, August 29 and will reopen on Tuesday, August 30th.

It’s likely that there will be some disruption to power supplies, wind damage and transportation problems that will take a little time to sort out. All client meetings scheduled for Monday have been cancelled. We expect to be back in business on Tuesday.

Unfortunately, we were not on the last ship to leave NYC this afternoon. We’ll be riding out the weather in New Jersey. If you are on the East Coast of the United States this weekend – keep safe!

Pharmacy Today publishes Women's Health and Melanoma articles by Pieter Droppert

Cover August Issue Pharmacy Today 219x300 Pharmacy Today publishes Women's Health and Melanoma articles by Pieter DroppertThe August 2011 issue of Pharmacy Today (the monthly magazine of the American Pharmacists Association) contains two articles written by Pieter Droppert.

In an update on what’s happened in women’s health over the past year, Pieter highlights the Institute of Medicine report on Women’s Health Research. A key finding of this report is that medical research has neglected the needs of women with the exception of those associated with reproduction.

Another topic covered in the update on Women’s Health was the clinical trial results from use of the aromatase inhibitor exemestane as a chemo-preventative agent.  Exemestane use reduced the risk of invasive breast cancer by 65% compared to placebo.

Pieter also reported on news from ASCO 2011, and how new drugs such as ipilimumab (YERVOY™) and vemurafenib (Zelboraf™) offer hope to patients with metastatic melanoma.

You can read both articles on the Pharmacy Today website (free online access).

ECCO ESMO Stockholm Cancer Conference September 2011

Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending.

Gamla Stan swe 300x187 ECCO ESMO Stockholm Cancer Conference September 2011Photo: Max Anderson

We will be at ECCO 16 – ESMO 36 in Stockholm from September 23 – 27, 2011.

The jointly organized multidisciplinary cancer congress of the European CanCer Organisation (ECCO ) and European Society for Medical Oncology (ESMO) covers a wide range of topics from basic and translational science to surgery, radiotherapy, medical oncology, advocacy and care.

ECCO ESMO Stockholm Cancer Congress Banner ECCO ESMO Stockholm Cancer Conference September 2011You can access the preliminary programme for the meeting here.

Given the early cut-off date for submission of abstracts for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, we expect the ECCO/ESMO Stockholm meeting will publish interesting data on a number of new products in development.

In anticipation of the meeting, Sally Church will be analyzing the abstracts (once they are available) for what’s hot and you can expect a pre-meeting video blog post.  If you missed Sally’s ASCO preview video, it is well worth watching.

Hope to see you in Stockholm.

Gamla stan 600px ECCO ESMO Stockholm Cancer Conference September 2011Photo: Stan Shebs

Pharma Strategy Blog reaches 900 blog post milestone

It takes desire, discipline and determination to blog regularly, and as a result many blogs fall by the wayside over time. However, Sally Church has been writing a blog on oncology, hematology, cancer science & biology, clinical trials and new product development for the past five years. It continues to go from strength to strength thanks to Sally’s passion for the area.

Sally recently announced on Pharma Strategy Blog that she had reached the 900 blog post milestone.  In recognition of this, Sally took the time to answer the follow questions:

  • Why do you blog?
  • How do you decide what to write about?
  • What makes a good blog post?
  • Looking back on 900 posts – which posts are most memorable?
  • What are your future goals for Pharma Strategy Blog?

You can find out Sally’s answers in the following video: